argenx SE American Depositary Shares (ARGX) Financial Statements

argenx SE American Depositary Shares

ARGX · Nasdaq

	FY2019	FY2018	FY2017
Net Income	-$162.97M	-$66.64M	-$28.08M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$29.13	$26.04	$33.07	8	↑2 ↓0
Dec 2027	$37.27	$29.98	$42.82	12	↑6 ↓1
Dec 2028	$48.29	$38.86	$54.80	8	↑4 ↓0
Dec 2029	$59.50	$45.43	$75.19	5	↑2 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: ARGX
Type: Stock
Sector: Health Care
Industry: Biological Products, (No Diagnostic Substances)
Exchange: Nasdaq

argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Key Issues

Bullish view

Zacks upgraded argenx to Rank #2 (Buy), explicitly citing growing optimism about its earnings prospects.

Bearish view

The stock still declined 3.18% across the supplied trading window, and the evidence provides no reported earnings figure or company update validating that optimism.

Analyst Consensus

See all

Buy

25 analysts

$991

Current

$1,182

Low

$1,185

Average

$1,182

High

Average target implies +19.52% versus the current price.

Earnings History

BeatMissNo estimate

argenx SE American Depositary Shares

Analyst Estimates

Peers